Folic acid intravenous - Endocyte

Drug Profile

Folic acid intravenous - Endocyte

Alternative Names: IV folic acid - Endocyte; Neocepri; Technetium Tc99m etarfolatide companion diagnostic - Endocyte

Latest Information Update: 21 May 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Endocyte
  • Class Antianaemics; Antidotes; Chemoprotectants; Chemosensitisers; Pterins; Small molecules; Vitamins
  • Mechanism of Action Single-photon emission-computed tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Submission Withdrawal Ovarian cancer

Most Recent Events

  • 16 May 2014 Regulatory submission withdrawn for Diagnostic imaging (patients with folate receptor-positive ovarian cancer) in European Union (IV) ,
  • 16 May 2014 Regulatory submission withdrawn for Ovarian cancer (diagnosis of patients with folate receptor-positive ovarian cancer) in European Union (IV) ,
  • 20 Mar 2014 Preregistration for Ovarian cancer (diagnosis of patients with folate receptor-positive ovarian cancer) in European Union (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top